Completed PHASE2 INTERVENTIONAL 4-arm NCT01007123

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation (ACCESS)

A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of Elobixibat in Patients With Chronic Idiopathic Constipation

Sponsor: Albireo

Conditions Chronic Constipation Constipation

Interventions A3309

Updated 7 times since 2017 Last updated: Feb 1, 2017 Started: Nov 30, 2009 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01007123, this PHASE2 trial focuses on Chronic Constipation and Constipation and remains completed. Sponsored by Albireo, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Albireo

Data source: AlbireoPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anaheim, United States , Anderson, United States , Annapolis, United States , Baltimore, United States , Boynton Beach, United States , Chandler, United States , Charlotte, United States , Chattanooga, United States , Chesterfield, United States and 33 more locations